| Trial ID: | L4041 |
| Source ID: | NCT06449235
|
| Associated Drug: |
Omarigliptin
|
| Title: |
Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh
|
| Acronym: |
|
| Status: |
NOT_YET_RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type2diabetes
|
| Interventions: |
DRUG: Omarigliptin|DRUG: Sulphonylureas|DRUG: Metformin|DRUG: Other DPP4-i|DRUG: Thiazolidinediones|DRUG: Alpha-Glucosidase Inhibitor|DRUG: Glucagon-Like Peptide-1|DRUG: Receptor Agonists (GLP1RA)|DRUG: SGLT2 inhibitors
|
| Outcome Measures: |
Primary: Glycemic Control as Measured by HbA1c Levels, Evaluation of the efficacy of omarigliptin in managing glycemic control among newly diagnosed Type 2 Diabetes Mellitus (T2DM) patients in a real-world clinical setting., Baseline assessment. Follow-up visits at 14 days, 3 months, and 6 months post-enrollment. |
|
| Sponsor/Collaborators: |
Sponsor: Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders | Collaborators: Pi Research and Development Center|Acme Laboratories Ltd.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
938
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2024-09
|
| Completion Date: |
2025-06
|
| Results First Posted: |
|
| Last Update Posted: |
2024-07-16
|
| Locations: |
BIRDEM General Hospital, Dhaka, 1000, Bangladesh
|
| URL: |
https://clinicaltrials.gov/show/NCT06449235
|
